Skip to main content

Table 4 Tumor Response by Immune-Related Adverse Event Occurrence

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Best Responsea irAE, n = 130 pts No irAE, n = 1405 pts
Complete Response (CR) 8 (6.2%) 67 (4.8%)
Partial Response (PR) 37 (28.5%) 239 (17%)
Stable Disease (SD) 48 (37%) 483 (34.4%)
Progressive Disease 32 (25%) 470 (33.5%)
Missing 5 (3.8%) 146 (10.4%)
CR + PR + SD (n, %) 93 (71%) 789 (56%)
bp = 0.0008
CR + PR (n, %) 45 (34.6%) 306 (21.8%)
cp = 0.0014
  1. irAE immune-related adverse event; pts.-patients;
  2. aBest response is determined from responses captured between baseline IL-2 administration and prior to subsequent treatment
  3. bFisher’s exact test comparing CR + PR + SD by irAE to no irAE
  4. cFisher’s exact test comparing best response by irAE to no irAE